ARASENS Trial with Darolutamide in Combination with Docetaxel and Androgen Deprivation Therapy Meets Primary Endpoint of Significantly Increasing Overall Survival in Patients with Metastatic Hormone-Sensitive Prostate Cancer

The Phase III ARASENS trial investigating the use of the oral androgen receptor inhibitor darolutamide in metastatic hormone-sensitive prostate cancer, darolutamide in combination with docetaxel and androgen deprivation therapy (ADT) significantly increased overall survival compared to placebo, docetaxel and ADT.
[Orion Corporation]
[zotpress userid=” items=’nan’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Therapeutic Potential of TRPM8 Antagonists in Prostate Cancer

Researchers characterized and investigated the effects of transient receptor potential melastatin-8 (TRPM8) modulators in prostate cancer aggressiveness disclosing the molecular mechanism underlying their biological activity.
[Scientific Reports]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Dynamic Prostate Cancer Transcriptome Analysis Delineates the Trajectory to Disease Progression

Scientists generated a comprehensive prostate cancer transcriptome atlas that described the roadmap to tumor progression in a qualitative and quantitative manner. Using patient-derived xenograft models, they functionally validated their observations and add single-cell resolution.
[Nature Communications]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Prostate Tumor-Induced Stromal Reprogramming Generates Tenascin C That Promotes Prostate Cancer Metastasis through YAP/TAZ Inhibition

Investigators showed that endothelial-to-osteoblast (EC-to-OSB) transition led to changes in the tumor microenvironment that increased the metastatic potential of prostate cancer (PCa) cells. They found that conditioned medium from EC-OSB hybrid cells increased the migration and survival of PC3-mm2 and C4-2B4 PCa cells.
[Oncogene]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

rAAV-Delivered PTEN Therapeutics for Prostate Cancer

The effect of PTEN on prostate cancer (PCa) cell migration, apoptosis and the cell cycle was analyzed in vitro using a wound healing assay and flow cytometry. The authors assessed the ability of intraprostatic and intratumoral injection of recombinant adeno-associated virus (rAAV) 9 expressing Pten or Cdkn1b to inhibit PCa progression.
[Molecular Therapy-Nucleic Acids]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
AbstractFull ArticleGraphical Abstract
Bookmark

No account yet? Register

Share

Transcriptional Regulation and Ubiquitination-Dependent Regulation of HnRNPK Oncogenic Function in Prostate Tumorigenesis

Researchers noted that heterogeneous nuclear ribonucleoprotein K (HnRNPK) emerged as an important player in the carcinogenesis process of prostate cancer (PrCa). miR-206 and miR-613 suppressed HnRNPK expression by targeting its 3’-UTR in PrCa cell lines in which HnRNPK was overexpressed.
[Cancer Cell International]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Bone Marrow Mesenchymal Stem Cells Promote the Progression of Prostate Cancer through the SDF-1/CXCR4 Axis In Vivo and Vitro

Scientists investigated the involvement of the SDF-1/CXCR4 axis in the process of bone marrow mesenchymal stem cells (BMMSC) homing in prostate cancer (PCa) in vivo and in vitro and suggested that BMMSCs could home and promote the proliferation and migration of PCa through the SDF-1/CXCR4 axis.
[Clinical and Translational Oncology]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Hsa_circ_0030586 Promotes Epithelial–Mesenchymal Transition in Prostate Cancer via PI3K-AKT Signaling

Investigators showed that hsa_circ_0030586 was significantly upregulated in prostate cancer (PCa) cells. Interfering with hsa_circ_0030586 in PC3 cells inhibited cell proliferation, migration, and invasion.
[Bioengineered]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Ring A/B-modified 17β-Hydroxywithanolide Analogues as Antiproliferative Agents for Prostate Cancer and Potentiators of Immunotherapy for Renal Carcinoma and Melanoma

Physachenolide C is a 17β-hydroxywithanolide natural product with a unique anticancer potential, as it exhibits potent and selective in vitro antiproliferative activity against prostate cancer (PC) cells. Researchers explored the effect of ring A/B modifications of physachenolide C on these biological activities.
[Journal of Natural Products]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
AbstractGraphical Abstract
Bookmark

No account yet? Register

Share

In Vivo Evaluation of Nanostructured Lipid Carrier Systems (NLCS) in Mice Bearing Prostate Cancer Tumors

Curmumin (CRN)-NLC nanoparticles were administrated to nude mice with LNCaP prostate cancer xenografts and demonstrated substantial tumor volume suppression with no weight loss compared to pure CRN.
[Drug Delivery and Translational Research]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full ArticleGraphical Abstract
Bookmark

No account yet? Register

Share

Tracing TET1 Expression in Prostate Cancer: Discovery of Malignant Cells with a Distinct Oncogenic Signature

Ten–eleven translocation methylcytosine dioxygenase 1 (TET1) is involved in DNA demethylation and transcriptional regulation, plays a key role in the maintenance of stem cell pluripotency, and is dysregulated in malignant cells. Researchers analyzed TET1 expression in prostate cancer.
[Clinical Epigenetics]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share
Share